Natera, Inc. (NASDAQ:NTRA) Shares Sold by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC reduced its holdings in Natera, Inc. (NASDAQ:NTRA - Free Report) by 31.0% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 768,512 shares of the medical research company's stock after selling 345,236 shares during the quarter. Allspring Global Investments Holdings LLC owned approximately 0.57% of Natera worth $108,091,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of NTRA. LRI Investments LLC bought a new position in Natera in the fourth quarter worth about $29,000. Rakuten Securities Inc. raised its position in shares of Natera by 117.8% during the 1st quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company's stock worth $31,000 after purchasing an additional 119 shares during the period. ORG Partners LLC bought a new stake in shares of Natera in the 1st quarter worth approximately $32,000. EverSource Wealth Advisors LLC lifted its holdings in shares of Natera by 372.9% in the 4th quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company's stock worth $52,000 after purchasing an additional 261 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC boosted its position in Natera by 1,328.0% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 357 shares of the medical research company's stock valued at $57,000 after purchasing an additional 332 shares during the period. 99.90% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on NTRA shares. Piper Sandler raised their target price on Natera from $205.00 to $210.00 and gave the company an "overweight" rating in a research note on Thursday, May 15th. Wall Street Zen downgraded shares of Natera from a "hold" rating to a "sell" rating in a research report on Saturday, May 17th. Barclays boosted their target price on shares of Natera from $160.00 to $190.00 and gave the company an "overweight" rating in a research note on Friday, May 9th. Morgan Stanley raised their price target on shares of Natera from $176.00 to $185.00 and gave the company an "overweight" rating in a research note on Wednesday, March 5th. Finally, UBS Group boosted their price objective on Natera from $211.00 to $218.00 and gave the stock a "buy" rating in a research report on Friday, May 9th. One equities research analyst has rated the stock with a sell rating and fifteen have given a buy rating to the company's stock. According to MarketBeat.com, Natera currently has a consensus rating of "Moderate Buy" and a consensus price target of $184.63.

Insiders Place Their Bets

In other Natera news, Director Gail Boxer Marcus sold 4,000 shares of the business's stock in a transaction dated Tuesday, June 10th. The stock was sold at an average price of $164.44, for a total transaction of $657,760.00. Following the sale, the director now owns 5,704 shares in the company, valued at approximately $937,965.76. The trade was a 41.22% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Michael Burkes Brophy sold 2,562 shares of Natera stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $138.41, for a total transaction of $354,606.42. Following the completion of the transaction, the chief financial officer now directly owns 75,557 shares in the company, valued at approximately $10,457,844.37. This trade represents a 3.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 59,755 shares of company stock worth $8,898,589. 7.60% of the stock is owned by insiders.

Natera Stock Performance

NTRA opened at $167.96 on Friday. Natera, Inc. has a one year low of $92.14 and a one year high of $183.00. The stock's fifty day moving average is $158.92 and its 200-day moving average is $158.53. The company has a market capitalization of $22.93 billion, a PE ratio of -114.26 and a beta of 1.74.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The medical research company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.09. Natera had a negative net margin of 10.36% and a negative return on equity of 18.29%. The firm had revenue of $501.83 million for the quarter, compared to analysts' expectations of $446.68 million. During the same period in the previous year, the business earned ($0.56) earnings per share. Natera's revenue for the quarter was up 36.5% compared to the same quarter last year. On average, equities research analysts forecast that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.